Total Funding
3
36
Total FundingSeed raised
Growth Score
-13 pts
Heat Score
-18 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
663793
Ascalon International is an oncology drug development company that creates and manages a portfolio of oncology drugs.
Edward L. Jacobs: Chief Executive Officer
Daniel Hoff: Chief Scientific Officer and DirectorPast Role: American Association for Cancer Research, President
About the Company
Ascalon International, Inc., an oncology drug development company, creates and manages a portfolio of oncology drugs. The company also conducts biomarker-based clinical trials in oncology. In addition, it focuses on developing products by clinical development and regulatory execution, either by establishment of a joint development with the product
owner or by acquisition of the product. The company has a strategic and operational alliance with Parexel. Ascalon International, Inc. was founded in 2009 and is based in Scottsdale, Arizona.
